In the field of bacterial pathogenicity research, the phenol-soluble regulatory protein (PSM) family has always been a focus of attention. Among them, PSMα2 (CAS: 1092844-32-0), as a core virulence factor of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), provides an important target for infectious disease research due to its mediated immunomodulatory effects.
PSMα2 is an α-helical amphoteric peptide with a formyl group at the N-terminus. Its unique structure determines its multiple functions in host-pathogen interactions. Studies have confirmed that this peptide can activate neutrophils by specifically binding to formyl peptide receptor 2 (FPR2), inducing a transient change in cytoplasmic calcium concentration, thereby triggering the production of reactive oxygen species (ROS). This receptor-dependent activation mechanism is closely related to the invasive infectivity of Staphylococcus aureus and is a key step in its pathogenic process.
More importantly, PSMα2 also possesses independent regulatory functions independent of FPR2. It can significantly downregulate the neutrophil response to other stimuli and exhibit a stronger cytolytic effect on apoptotic neutrophils. Interestingly, ROS produced by the neutrophil myeloperoxidase-H₂O₂ system can inversely inactivate PSMα2, forming a dynamic balance between the host and pathogen. This discovery provides a new perspective on understanding the body's natural defense mechanisms against bacterial virulence.
In clinical research, elucidating the mechanism of action of PSMα2 has significant translational value. The incidence of severe infections caused by CA-MRSA is increasing year by year, and the combination of its high virulence and antibiotic resistance poses a significant challenge to treatment. As a core virulence factor, PSMα2's mediated immune regulatory pathways hold promise as a target for the design of novel anti-infective drugs. Related studies have confirmed that targeting the regulation of PSMα2 activity can significantly affect the pathogenicity of Staphylococcus aureus, opening up new avenues for the treatment of drug-resistant bacterial infections.
From basic research to clinical translation, each functional discovery of PSMα2 (1092844-32-0) has advanced our understanding of the pathogenic mechanisms of Staphylococcus aureus. In the future, as research deepens, this key peptide will provide stronger theoretical support and technological directions for the prevention and control of infectious diseases.
